

Challenges and drivers for development of Long Acting Injectables

SMi Reports: Renowned industry experts from MedinCell Janssen to present at the Pre-Filled Syringes UK pre-conference workshop taking place 12th January 2021

LONDON, KENSINGTON, UNITED KINGDOM, October 5, 2020 /EINPresswire.com/ -- The Workshop will give an overview of the landscape of long acting injectable technologies, addressing the key barriers facing development in industry and discussing strategies in overcoming hurdles in sustained-release delivery. Delegates will engage in an interactive case study review to explore the best approaches and strategies for long



acting injectable development and optimal delivery. Further discussion will delve into the future potential for long-acting injectables.

View the full agenda and speaker line-up online: www.<u>pre-filled</u>-<u>syringes</u>.com/einpr3

Benefits of attending:

- •Assess the current landscape for fragile molecule formulations and delivery
- •Explore real world examples through injectable device case studies
- •Discuss considerations and strategies for successful long-acting injectable delivery
- •Gain insight into the future landscape of long acting injectables

Workshop Leaders discussing:

Dr Joël Richard, Chief Development Officer, MedinCell René Holm, Head & Scientific Director, Janssen

AN OVERVIEW OF TECHNOLOGIES FOR LONG ACTING INJECTABLES

- Durrent successful technologies in industry
- •What are the limitations and barriers facing development?
- Competitive advantages of injectable in situ forming implant technologies
- •How do we select compounds for long acting injectables?

FORMULATIONS OF FRAGILE MOLECULES

- Current landscape for delivery of fragile molecules
- •Specific formulation challenges for peptides and proteins
- Dvercoming hurdles in fragile molecule sustained-release delivery

CASE STUDY INTRODUCTION

- •Delegates will be presented with a case study overview of the BEPO [®] long acting injectable
- •Recent progress of BEPO ®
- Thallenges in development of the long acting injectables and considerations in formulation development

INTERACTIVE CASE STUDY REVIEW

- •Delegates will be tasked to assess and discuss:
- Best approaches for development
- Btrategies to overcome formulation challenges
- Brainstorm improvements for optimal delivery
- Discussion of lessons learned from the exercise
- •Buture potential for long acting injectables

Register online: www.pre-filled-syringes.com/einpr3

Who should attend:

- Drug-delivery developers
- Medical Device Engineers
- •Brimary Packaging material designers
- Becondary packagers
- •Smart device developers
- Training device developers
- Device-safety solution providers
- Drug developers

Pre-Filled Syringes and <u>Injectable Drug Devices</u> Conference 13th – 14th January 2021 London, UK --- ENDS -

Contact Information:

For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smionline.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu SMi Group 02078276088 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/527731120

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.